Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
March 7, 2017
Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
March 3, 2017
Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting
February 27, 2017
Revance Releases Fourth Quarter and Full Year 2016 Results
February 22, 2017
Revance to Participate in Upcoming Investor Conferences
February 16, 2017
Revance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
January 26, 2017
BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
January 18, 2017
Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
January 5, 2017
Revance Provides Clinical Milestones and Financial Outlook for 2017
December 12, 2016
Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial
December 7, 2016
Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
Displaying 211 - 220 of 305